SNIPR Biome Receives CARB-X Funding to Test...
CMN Briefs
Apr. 22, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
SNIPR Biome
Main focus: Treatment of bacterial infections
Company stage: Pre-clinical
Diseases: Bloodstream infections caused by E. coli, other infections
Genome editing tool: CRISPR-Cas
Funding stage: Private
Location: Copenhagen, Denmark
Website: https://www.sniprbiome.com/
Partners: Novo Nordisk
SNIPR Biome is a Danish, pre-clinical stage company. The company is focused on novel CRISPR-based antibacterial therapies. The company has patents on several CRISPR-Cas technologies including the Cas9, Cas3 and Cas12a enzymes. While SNIPR Biome has not revealed an official pipeline, it has disclosed the use of its DNA-based CRISPR-guided vector platform to generate next-generation antibiotic therapies.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
